Kayla Marsh

Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab

Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla et al. · Nature Cancer · 2020 · 480 citations

Medicine, Oncology, Pharmacology +16

Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA

Derek Wong, Ping Luo, Leslie E. Oldfield et al. · Cancer Discovery · 2023 · 56 citations · Full text

Medicine, Molecular Biology, Oncology +17

Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Eric Y. Stutheit-Zhao, Enrique Sanz‐García, Zhihui Amy Liu et al. · Cancer Discovery · 2024 · 31 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Stéphanie Lheureux, Stephenie D. Prokopec, Leslie E. Oldfield et al. · Clinical Cancer Research · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy

Daniel Vilarim Araújo, Ao Wang, Dax Torti et al. · JNCI Cancer Spectrum · 2020 · 20 citations · Full text

Medicine, Cancer Biology, Oncology +17